Explore New Innovations with Dahua Full-color Camera
22.11.2022 15:45:00 EET | Business Wire | Press release
Dahua Technology, a world-leading video-centric smart IoT solution and service provider, has been accelerating the innovation and exploration of Full-color Technology. Featuring TiOC, Panoramic, Zoom and 4K, the new generation of Dahua full-color series provides a wide range of low-light solutions that integrate different intelligent technologies to solve pain points in various scenarios, allowing installers and end users to choose the ideal solution that best suits their needs.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221121005376/en/
Inadequate availability of light is one of the major challenges of every monitoring system. Images taken under such lighting condition are often not clear, have detail loss, and even contain noise, making it difficult to detect or trace back targets in case of an event. The Dahua Full-color cameras were developed to address these demanding monitoring challenges. With remarkable offerings such as dual lens, vari-focal lens, 4K resolution, and AI features, this technology offers a wide-range of products and solutions that can effectively solve the arduous monitoring pain points of end-users and provide clear and vivid images of the monitored scene 24/7. (Photo: Business Wire)
Full-color + TiOC: effective deterrent against intruders
The Dahua TiOC (three-in-one camera) integrates Smart Dual Illuminators, Active Deterrence, and AI to offer a pro-active monitoring solution that can effectively warn off intruders. The combination of Dahua’s industry-leading full-color technology with powerful AI functions and real-time Active Deterrence warnings makes it suitable for places that require 24/7 security, such as villas, shops, warehouses, etc., helping to reduce false alarm rates, improve target search efficiency, generally optimize system operation, and reduce costs.
Full-color + Panoramic: the whole scene in vivid color
The Dahua Full-color Dual Lens 180° Panoramic PTZ & IPC are equipped with dual sensors that deliver a 180-degree field of view. It adopts the Dahua pixel-level seamless fusion algorithm to splice images into horizontal 180° monitoring scene, providing users with brilliant full-color and panoramic images. Featuring wide-area coverage, it is an excellent alternative to daunting installation of multiple cameras just to cover a large scene. Thanks to Full-color Technology, the intelligent panoramic camera can provide clear color images even at night, which is essential for 24/7 continuous monitoring in large application scenarios such as squares, hallways, and parking lots.
Full-color + ZOOM: vari-focal zoom in with vivid color
The Dahua Full-color Vari-focal Camera boasts approx. 5x optical zoom capability and auto-focus function. These cameras provide clear monitoring scene details even after zooming in, capture vivid color images in dark environments, and also allow users to directly adjust the camera’s focus according to the actual scene, which is convenient and time-saving.
Full-color + 4K: Realistic 4K UHD image quality
The Dahua Full-color 4K Camera delivers enhanced color images and video footages 24/7. It adopts 1/1.2” image sensor (currently Dahua's best low-light IPC sensor) that provides 110% pixel size increase compared to common 8MP sensor. Combined with a F1.0 large aperture, more available light can be captured to provide clear and vivid images, which is conductive to accurate video analysis.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221121005376/en/
Contact information
Zoe Xu (xu_shuyi@dahuatech.com )
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom